Fig. 3. KRAS-G12C inhibitor with cetuximab combination showed promising effects in PDCs in 3D and in vivo experiments.
a Evaluation of sotorasib plus cetuximab combination efficacy in a 3D culture. b JC288 cells were subcutaneously transplanted into BALB/c nu/nu mice. Once the average tumor volume reached approximately 150 mm3, the mice (N = 4) were treated once daily with sotorasib (100 mg/Kg), or sotorasib plus cetuximab (1 mg/body) for 5 days/week. Data were expressed as the mean ± SD, and the Mann–Whitney U-test was used between the control group and the sotorasib plus cetuximab group.